Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Marketed
Current status date:
2020-04-16
Original market date: See footnote 1
2020-04-16
Product name:
KANJINTI
DIN:
02496690
Product Monograph/Veterinary Labelling:
Date:
2020-02-27
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
AMGEN CANADA INC
6775 Financial Drive, Suite 100
Mississauga
Ontario
Canada
L5N 0A4
Class:
Human
Dosage form(s):
Powder For Solution, Kit
Route(s) of administration:
Intravenous
Number of active ingredient(s):
1
Schedule(s):
Schedule D, Prescription
Biosimilar Biologic Drug:
No
American Hospital Formulary Service (AHFS): See footnote 3
10:00.00 ANTINEOPLASTIC AGENTS
Anatomical Therapeutic Chemical (ATC): See footnote 4
L01XC03 TRASTUZUMAB
Active ingredient group (AIG) number:See footnote 5
0154252004
| Active ingredient(s) | Strength |
|---|---|
| TRASTUZUMAB | 420 MG / VIAL |